May 26, 2026: MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026

MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026 MaaT013 (Xervyteg®): In May 2026, the Company was informed of a “negative trend” opinion on its Marketing Authorization Application from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), ahead of the expected CHMP formal vote in June; the Company plans to…